BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15061647)

  • 1. Effect of combination therapy with a calcium channel blocker and an angiotensin-converting enzyme inhibitor on renal hypertrophy and urinary albumin excretion in diabetic rats.
    Nielsen B; Grønbaek H; Osterby R; Flyvbjerg A
    Exp Diabesity Res; 2003; 4(3):191-9. PubMed ID: 15061647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
    Jackson B; Cubela R; Debrevi L; Whitty M; Johnston CI
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S167-9. PubMed ID: 2455124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats.
    Nielsen B; Grønbaek H; Osterby R; Flyvbjerg A
    Am J Kidney Dis; 2000 Aug; 36(2):368-77. PubMed ID: 10922316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes.
    Mosconi L; Ruggenenti P; Perna A; Mecca G; Remuzzi G
    Kidney Int Suppl; 1996 Jun; 55():S91-3. PubMed ID: 8743521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
    Volpini RA; da Silva CG; Costa RS; Coimbra TM
    Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition.
    Navarro JF; Milena FJ; Mora C; León C; Claverie F; Flores C; García J
    Kidney Int Suppl; 2005 Dec; (99):S98-102. PubMed ID: 16336586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    Navarro JF; Milena FJ; Mora C; León C; García J
    Am J Nephrol; 2006; 26(6):562-70. PubMed ID: 17167242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker.
    Bianchi S; Bigazzi R; Baldari G; Campese VM
    Am J Hypertens; 1991 Apr; 4(4 Pt 1):291-6. PubMed ID: 2059393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria.
    Piñol C; Cobos A; Cases A; Esmatges E; Soler J; Closas J; Pascual R; Planas J
    Kidney Int Suppl; 1996 Jun; 55():S85-7. PubMed ID: 8743519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients.
    Deyneli O; Yavuz D; Velioglu A; Cacina H; Aksoy N; Haklar G; Taga Y; Akalin S
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):98-103. PubMed ID: 17083064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study.
    Sano T; Hotta N; Kawamura T; Matsumae H; Chaya S; Sasaki H; Nakayama M; Hara T; Matsuo S; Sakamoto N
    Diabet Med; 1996 Feb; 13(2):120-4. PubMed ID: 8641115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium channel blocker nitrendipine attenuates renal and glomerular hypertrophy in diabetic rats.
    Nielsen B; Gronbaek H; Osterby R; Orskov H; Flyvbjerg A
    Exp Nephrol; 1999; 7(3):242-50. PubMed ID: 10352365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy.
    Kopf D; Schmitz H; Beyer J; Frank M; Bockisch A; Lehnert H
    Diabetes Nutr Metab; 2001 Oct; 14(5):245-52. PubMed ID: 11806464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.
    Poulsen PL
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):17-26. PubMed ID: 12692749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
    Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.